# Mangoceuticals, Inc.: financial statements, quarterly

MGRX · Nasdaq · CIK 1938046 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mgrx.md) · [Financials](/companies/mgrx/financials.md) · [Filings](/companies/mgrx/filings.md) · [Insiders](/companies/mgrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mgrx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [245](/filings/0001493152-24-045895.md) | [244 d](/filings/0001641172-25-000085.md) | [214](/filings/0001641172-25-011047.md) | [163](/filings/0001493152-25-023566.md) | [133](/filings/0001493152-25-023640.md) | [105 d](/filings/0001493152-26-014478.md) | [109](/filings/0001493152-26-024426.md) | [168](/filings/0001493152-26-037873.md) | [84.2](/filings/0001493152-25-023640.md) | [94.4 d](/filings/0001493152-26-014478.md) | [67.9](/filings/0001493152-26-024426.md) | [68.8](/filings/0001493152-26-037873.md) |
| Cost of revenue | $k | [52.2](/filings/0001493152-24-045895.md) | [53.4 d](/filings/0001641172-25-000085.md) | [20.8](/filings/0001641172-25-011047.md) | [29.7](/filings/0001493152-25-023566.md) | [21.5](/filings/0001493152-25-023640.md) | [21.3 d](/filings/0001493152-26-014478.md) | [24.7](/filings/0001493152-26-024426.md) | [18.8](/filings/0001493152-26-037873.md) | [2.4](/filings/0001493152-25-023640.md) | [8.5 d](/filings/0001493152-26-014478.md) | [8.2](/filings/0001493152-26-024426.md) | [10.4](/filings/0001493152-26-037873.md) |
| Gross profit | $k | [145](/filings/0001493152-24-045895.md) | [143 d](/filings/0001641172-25-000085.md) | [147](/filings/0001641172-25-011047.md) | [69.8](/filings/0001493152-25-023566.md) | [82.7](/filings/0001493152-25-023640.md) | [80.1 d](/filings/0001493152-26-014478.md) | [62.1](/filings/0001493152-26-024426.md) | [89.9](/filings/0001493152-26-037873.md) | [50.9](/filings/0001493152-25-023640.md) | [47.5 d](/filings/0001493152-26-014478.md) | [29.0](/filings/0001493152-26-024426.md) | [44.2](/filings/0001493152-26-037873.md) |
| Operating income | $k | [(1,799)](/filings/0001493152-24-045895.md) | [(2,568) d](/filings/0001641172-25-000085.md) | [(2,368)](/filings/0001641172-25-011047.md) | [(2,169)](/filings/0001493152-25-023566.md) | [(1,758)](/filings/0001493152-25-023640.md) | [(1,678) d](/filings/0001493152-26-014478.md) | [(4,576)](/filings/0001493152-26-024426.md) | [(5,268)](/filings/0001493152-26-037873.md) | [(7,543)](/filings/0001493152-25-023640.md) | [(368) d](/filings/0001493152-26-014478.md) | [(3,126)](/filings/0001493152-26-024426.md) | [(1,033)](/filings/0001493152-26-037873.md) |
| Interest expense | $k | [0.0 d](/filings/0001493152-24-045895.md) | [0.0 d](/filings/0001641172-25-000085.md) | not reported | not reported | not reported | not reported | [(13.7)](/filings/0001493152-26-024426.md) | [21.7](/filings/0001493152-26-037873.md) | [75.9](/filings/0001493152-25-023640.md) | [19.7 d](/filings/0001493152-26-014478.md) | not reported | not reported |
| Net income | $k | [(1,799)](/filings/0001493152-24-045895.md) | [(2,568) d](/filings/0001641172-25-000085.md) | [(2,368)](/filings/0001641172-25-011047.md) | [(2,391)](/filings/0001493152-25-023566.md) | [(1,999)](/filings/0001493152-25-023640.md) | [(1,948) d](/filings/0001493152-26-014478.md) | [(4,839)](/filings/0001493152-26-024426.md) | [(5,416)](/filings/0001493152-26-037873.md) | [(7,618)](/filings/0001493152-25-023640.md) | [(2,770) d](/filings/0001493152-26-014478.md) | [(3,403)](/filings/0001493152-26-024426.md) | [(1,313)](/filings/0001493152-26-037873.md) |
| Diluted EPS | $ per share | [(1.70)](/filings/0001493152-24-045895.md) | not reported | [(1.50)](/filings/0001641172-25-011047.md) | [(1.37)](/filings/0001493152-25-023566.md) | [(1.14)](/filings/0001493152-25-023640.md) | not reported | [(1.12)](/filings/0001493152-26-024426.md) | [(0.57)](/filings/0001493152-26-037873.md) | [(0.69)](/filings/0001493152-25-023640.md) | not reported | [(0.22)](/filings/0001493152-26-024426.md) | [(0.09)](/filings/0001493152-26-037873.md) |
| Basic EPS | $ per share | [(1.70)](/filings/0001493152-24-045895.md) | not reported | [(1.50)](/filings/0001641172-25-011047.md) | [(1.37)](/filings/0001493152-25-023566.md) | [(1.14)](/filings/0001493152-25-023640.md) | not reported | [(1.12)](/filings/0001493152-26-024426.md) | [(0.57)](/filings/0001493152-26-037873.md) | [(0.69)](/filings/0001493152-25-023640.md) | not reported | [(0.22)](/filings/0001493152-26-024426.md) | [(0.09)](/filings/0001493152-26-037873.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | period not labelled (2025-02-11) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.7](/filings/0001641172-25-000085.md) | [0.0](/filings/0001493152-24-019960.md) | [0.5](/filings/0001493152-24-032410.md) | [0.1](/filings/0001493152-24-045895.md) | [0.1](/filings/0001493152-26-014478.md) | [0.3](/filings/0001641172-25-000085.md) | [0.1](/filings/0001641172-25-011047.md) | [0.1](/filings/0001493152-25-023566.md) | [0.5](/filings/0001493152-25-023640.md) | [1.5](/filings/0001493152-26-037873.md) | [0.2](/filings/0001493152-26-024426.md) | [0.2](/filings/0001493152-26-037873.md) |
| Current assets | $m | [0.8](/filings/0001641172-25-000085.md) | [0.1](/filings/0001493152-24-019960.md) | [0.5](/filings/0001493152-24-032410.md) | [0.1](/filings/0001493152-24-045895.md) | [0.1](/filings/0001493152-26-014478.md) | not reported | [0.2](/filings/0001641172-25-011047.md) | [0.1](/filings/0001493152-25-023566.md) | [0.6](/filings/0001493152-25-023640.md) | [1.5](/filings/0001493152-26-037873.md) | [0.2](/filings/0001493152-26-024426.md) | [0.2](/filings/0001493152-26-037873.md) |
| Total assets | $m | [1.1](/filings/0001641172-25-000085.md) | [0.3](/filings/0001493152-24-019960.md) | [15.2](/filings/0001493152-24-032410.md) | [14.8](/filings/0001493152-24-045895.md) | [15.4](/filings/0001493152-26-014478.md) | not reported | [21.8](/filings/0001641172-25-011047.md) | [20.8](/filings/0001493152-25-023566.md) | [16.5](/filings/0001493152-25-023640.md) | [16.1](/filings/0001493152-26-037873.md) | [14.4](/filings/0001493152-26-024426.md) | [14.2](/filings/0001493152-26-037873.md) |
| Current liabilities | $m | [0.2](/filings/0001641172-25-000085.md) | [1.2](/filings/0001493152-24-019960.md) | [1.4](/filings/0001493152-24-032410.md) | [1.4](/filings/0001493152-24-045895.md) | [1.4](/filings/0001493152-26-014478.md) | not reported | [1.5](/filings/0001641172-25-011047.md) | [1.6](/filings/0001493152-25-023566.md) | [0.8](/filings/0001493152-25-023640.md) | [0.9](/filings/0001493152-26-037873.md) | [0.7](/filings/0001493152-26-024426.md) | [1.4](/filings/0001493152-26-037873.md) |
| Total liabilities | $m | [0.3](/filings/0001641172-25-000085.md) | [1.3](/filings/0001493152-24-019960.md) | [1.4](/filings/0001493152-24-032410.md) | [1.4](/filings/0001493152-24-045895.md) | [1.4](/filings/0001493152-26-014478.md) | not reported | [1.5](/filings/0001641172-25-011047.md) | [1.6](/filings/0001493152-25-023566.md) | [0.8](/filings/0001493152-25-023640.md) | [0.9](/filings/0001493152-26-037873.md) | [1.0](/filings/0001493152-26-024426.md) | [1.6](/filings/0001493152-26-037873.md) |
| Shareholders' equity | $m | [0.8](/filings/0001641172-25-000085.md) | [(1.0)](/filings/0001493152-24-019960.md) | [13.8](/filings/0001493152-24-032410.md) | [13.4](/filings/0001493152-24-045895.md) | [13.9](/filings/0001493152-26-014478.md) | not reported | [20.3](/filings/0001641172-25-011047.md) | [19.2](/filings/0001493152-25-023566.md) | [15.7](/filings/0001493152-25-023640.md) | [15.2](/filings/0001493152-26-037873.md) | [13.5](/filings/0001493152-26-024426.md) | [12.5](/filings/0001493152-26-037873.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,711) d](/filings/0001493152-24-045895.md) | [(1,698) d](/filings/0001641172-25-000085.md) | [(991)](/filings/0001641172-25-011047.md) | [(1,577) d](/filings/0001493152-25-023566.md) | [(1,166) d](/filings/0001493152-25-023640.md) | [(1,130) d](/filings/0001493152-26-014478.md) | [(2,275)](/filings/0001493152-26-024426.md) | [(1,256) d](/filings/0001493152-26-037873.md) | [(1,241) d](/filings/0001493152-25-023640.md) | [(1,078) d](/filings/0001493152-26-014478.md) | [(1,311)](/filings/0001493152-26-024426.md) | [(261) d](/filings/0001493152-26-037873.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001493152-24-045895.md) | [0.0 d](/filings/0001641172-25-000085.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.0](/filings/0001493152-23-038526.md) | [11.3](/filings/0001493152-24-019960.md) | [15.8](/filings/0001493152-24-032410.md) | [1.1](/filings/0001493152-24-045895.md) | [1.6](/filings/0001641172-25-011047.md) | [1.7](/filings/0001493152-25-023566.md) | [2.0](/filings/0001493152-25-023640.md) | [4.6](/filings/0001493152-26-024426.md) | [10.0](/filings/0001493152-26-037873.md) | [11.5](/filings/0001493152-25-023640.md) | [16.5](/filings/0001493152-26-024426.md) | [17.1](/filings/0001493152-26-037873.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 21,567,422 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037873.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.